United States Durable Medical Equipment Market Outlook to 2030: Size, Share, Growth and Trends

The United States Durable Medical Equipment Market was valued at USD 79,500 Mn in 2024 on an industry-revenue basis. The measurement lens captures revenue at the point of sale or supplier service realization across manufacturers, distributors, and DME suppliers serving hospital, home healthcare, skilled nursing, ambulatory surgery center, and outpatient settings. It excludes implantable devices and single-use consumables. That matters because the revenue pool is shaped not only by device shipments, but also by rental economics, service delivery, and reimbursement-linked fulfillment across multiple care settings.

On the locked base trajectory, the United States Durable Medical Equipment Market reaches USD 112,519 Mn by 2030. This extends a pre-validated USD 106,200 Mn market value in 2029 and is consistent with a base-case growth path of about 5.95% annually. The expansion is credible because volume also rises, from 310 million units in 2024 to roughly 415 million units by 2030, while revenue per unit improves modestly. In other words, growth is not purely price-driven; it is supported by higher usage intensity and richer product-service mix.

The profit pool is shifting toward home-based monitoring, respiratory support, and service-heavy equipment workflows rather than static institutional furniture. Monitoring & Therapeutic Devices already account for USD 46,800 Mn, or 58.9% of the 2024 market, while the fastest-growing sub-channel is home healthcare-linked monitoring and respiratory equipment at 8.6% CAGR. These segments carry better economics because they combine device value with recurring delivery, patient setup, compliance support, remote monitoring, and replacement cycles. By contrast, Medical Furniture & Hospital Beds are growing more slowly at 3.8% CAGR, reflecting lower mix uplift and more procurement commoditization.

The most material risk is reimbursement and compliance pressure rather than demand weakness. CMS-linked fee schedules cap pricing in standardized categories, while MedPAC has already recommended a 7% reduction to 2024 home health base payment rates for 2025. At the same time, DMEPOS accreditation, documentation, and claims rules raise fixed operating costs and denial exposure. This means that even in a growing market, weaker suppliers can lose margin if they lack audit readiness, claims accuracy, and scale purchasing leverage. The downside scenario still leaves the market sizable, but the winners will be those with clean execution under reimbursement scrutiny.

The United States is the largest market in the selected developed-market peer set by a wide margin. At USD 79,500 Mn in 2024, it is materially larger than estimated peer markets such as Japan at USD 17,000 Mn and Germany at USD 14,200 Mn. Its advantage comes from a combination of elderly population scale, high healthcare spending per capita, broad home-care infrastructure, and deep reimbursement channels. Growth is not the highest among all comparators, but it is strong enough to combine scale and expansion, which is typically more valuable than hypergrowth in a smaller market.

Aging remains the single most important structural demand driver because it amplifies utilization across nearly every major DME category. The U.S. population aged 65 and older reached 61.2 million in 2024, and this cohort has disproportionate needs in mobility support, chronic monitoring, oxygen therapy, sleep therapy, and bathroom safety. The effect is magnified by disease burden, because CDC continues to note that 6 in 10 adults live with at least one chronic disease. This combination creates durable, non-cyclical demand that is less dependent on discretionary healthcare spending than many adjacent device categories.